XML 39 R18.htm IDEA: XBRL DOCUMENT
v3.23.1

Segments of Business and Geographic Areas | 3 Months Ended
--- | ---
Apr. 02, 2023
Segment Reporting [Abstract] |
Segments of Business and Geographic Areas | SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS SALES BY SEGMENT OF BUSINESS
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  | Percent Change |  |  |  |  |  |
CONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  |
OTC |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | $ | 745 |  |  | 670 |  |  | 11.0 | % |  |  |  |  |  |
International |  | 897 |  |  | 791 |  |  | 13.5 |  |  |  |  |  |  |
Worldwide |  | 1,642 |  |  | 1,461 |  |  | 12.4 |  |  |  |  |  |  |
Skin Health/Beauty |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 617 |  |  | 544 |  |  | 13.4 |  |  |  |  |  |  |
International |  | 493 |  |  | 468 |  |  | 5.3 |  |  |  |  |  |  |
Worldwide |  | 1,110 |  |  | 1,012 |  |  | 9.7 |  |  |  |  |  |  |
Oral Care |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 159 |  |  | 143 |  |  | 11.6 |  |  |  |  |  |  |
International |  | 202 |  |  | 223 |  |  | (9.6) |  |  |  |  |  |  |
Worldwide |  | 361 |  |  | 366 |  |  | (1.3) |  |  |  |  |  |  |
Baby Care |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 96 |  |  | 85 |  |  | 13.0 |  |  |  |  |  |  |
International |  | 263 |  |  | 270 |  |  | (2.8) |  |  |  |  |  |  |
Worldwide |  | 359 |  |  | 355 |  |  | 1.0 |  |  |  |  |  |  |
Women’s Health |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 3 |  |  | 3 |  |  | 1.8 |  |  |  |  |  |  |
International |  | 214 |  |  | 224 |  |  | (4.9) |  |  |  |  |  |  |
Worldwide |  | 217 |  |  | 228 |  |  | (4.8) |  |  |  |  |  |  |
Wound Care/Other |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 115 |  |  | 112 |  |  | 2.6 |  |  |  |  |  |  |
International |  | 49 |  |  | 52 |  |  | (6.0) |  |  |  |  |  |  |
Worldwide |  | 164 |  |  | 164 |  |  | (0.1) |  |  |  |  |  |  |
TOTAL CONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,735 |  |  | 1,557 |  |  | 11.4 |  |  |  |  |  |  |
International |  | 2,117 |  |  | 2,029 |  |  | 4.4 |  |  |  |  |  |  |
Worldwide |  | 3,852 |  |  | 3,586 |  |  | 7.4 |  |  |  |  |  |  |
PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  |
Immunology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,448 |  |  | 2,501 |  |  | (2.1) |  |  |  |  |  |  |
International |  | 1,664 |  |  | 1,617 |  |  | 2.9 |  |  |  |  |  |  |
Worldwide |  | 4,112 |  |  | 4,119 |  |  | (0.2) |  |  |  |  |  |  |
REMICADE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 276 |  |  | 358 |  |  | (22.8) |  |  |  |  |  |  |
U.S. Exports |  | 41 |  |  | 80 |  |  | (48.8) |  |  |  |  |  |  |
International |  | 170 |  |  | 225 |  |  | (24.4) |  |  |  |  |  |  |
Worldwide |  | 487 |  |  | 663 |  |  | (26.5) |  |  |  |  |  |  |
SIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 271 |  |  | 287 |  |  | (5.6) |  |  |  |  |  |  |
International |  | 266 |  |  | 283 |  |  | (6.1) |  |  |  |  |  |  |
Worldwide |  | 537 |  |  | 571 |  |  | (5.8) |  |  |  |  |  |  |
STELARA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,451 |  |  | 1,379 |  |  | 5.2 |  |  |  |  |  |  |
International |  | 993 |  |  | 909 |  |  | 9.3 |  |  |  |  |  |  |
Worldwide |  | 2,444 |  |  | 2,288 |  |  | 6.8 |  |  |  |  |  |  |
TREMFYA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 406 |  |  | 391 |  |  | 3.9 |  |  |  |  |  |  |
International |  | 234 |  |  | 199 |  |  | 17.3 |  |  |  |  |  |  |
Worldwide |  | 640 |  |  | 590 |  |  | 8.4 |  |  |  |  |  |  |
OTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 3 |  |  | 6 |  |  | (51.2) |  |  |  |  |  |  |
International |  | 0 |  | 0 |  | — |  |  |  |  |  |  |
Worldwide |  | 3 |  |  | 6 |  |  | (51.3) |  |  |  |  |  |  |
Infectious Diseases |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 392 |  |  | 461 |  |  | (14.9) |  |  |  |  |  |  |
International |  | 1,193 |  |  | 836 |  |  | 42.8 |  |  |  |  |  |  |
Worldwide |  | 1,586 |  |  | 1,297 |  |  | 22.3 |  |  |  |  |  |  |
COVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 0 |  | 75 |  |  | * |  |  |  |  |  |
International |  | 747 |  |  | 382 |  |  | 95.6 |  |  |  |  |  |  |
Worldwide |  | 747 |  |  | 457 |  |  | 63.4 |  |  |  |  |  |  |
EDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 9 |  |  | 9 |  |  | (1.4) |  |  |  |  |  |  |
International |  | 271 |  |  | 239 |  |  | 13.4 |  |  |  |  |  |  |
Worldwide |  | 280 |  |  | 248 |  |  | 12.8 |  |  |  |  |  |  |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 378 |  |  | 369 |  |  | 2.5 |  |  |  |  |  |  |
International |  | 99 |  |  | 132 |  |  | (25.2) |  |  |  |  |  |  |
Worldwide |  | 477 |  |  | 501 |  |  | (4.8) |  |  |  |  |  |  |
OTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 5 |  |  | 8 |  |  | (33.1) |  |  |  |  |  |  |
International |  | 77 |  |  | 83 |  |  | (7.6) |  |  |  |  |  |  |
Worldwide |  | 82 |  |  | 91 |  |  | (9.8) |  |  |  |  |  |  |
Neuroscience |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 978 |  |  | 843 |  |  | 16.0 |  |  |  |  |  |  |
International |  | 826 |  |  | 898 |  |  | (8.1) |  |  |  |  |  |  |
Worldwide |  | 1,804 |  |  | 1,741 |  |  | 3.6 |  |  |  |  |  |  |
CONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 70 |  |  | 35 |  |  | * |  |  |  |  |  |
International |  | 136 |  |  | 122 |  |  | 11.4 |  |  |  |  |  |  |
Worldwide |  | 206 |  |  | 157 |  |  | 31.4 |  |  |  |  |  |  |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 713 |  |  | 661 |  |  | 7.9 |  |  |  |  |  |  |
International |  | 331 |  |  | 387 |  |  | (14.6) |  |  |  |  |  |  |
Worldwide |  | 1,044 |  |  | 1,048 |  |  | (0.4) |  |  |  |  |  |  |
SPRAVATO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 111 |  |  | 61 |  |  | 82.4 |  |  |  |  |  |  |
International |  | 20 |  |  | 9 |  |  | * |  |  |  |  |  |
Worldwide |  | 131 |  |  | 70 |  |  | 86.9 |  |  |  |  |  |  |
OTHER NEUROSCIENCE(1) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 84 |  |  | 86 |  |  | (3.5) |  |  |  |  |  |  |
International |  | 339 |  |  | 380 |  |  | (10.7) |  |  |  |  |  |  |
Worldwide |  | 423 |  |  | 467 |  |  | (9.4) |  |  |  |  |  |  |
Oncology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,889 |  |  | 1,582 |  |  | 19.4 |  |  |  |  |  |  |
International |  | 2,223 |  |  | 2,369 |  |  | (6.1) |  |  |  |  |  |  |
Worldwide |  | 4,112 |  |  | 3,950 |  |  | 4.1 |  |  |  |  |  |  |
CARVYKTI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 70 |  |  | — |  |  | * |  |  |  |  |  |
International |  | 2 |  |  | — |  |  | * |  |  |  |  |  |
Worldwide |  | 72 |  |  | — |  |  | * |  |  |  |  |  |
DARZALEX |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,191 |  |  | 953 |  |  | 25.0 |  |  |  |  |  |  |
International |  | 1,072 |  |  | 903 |  |  | 18.8 |  |  |  |  |  |  |
Worldwide |  | 2,264 |  |  | 1,856 |  |  | 22.0 |  |  |  |  |  |  |
ERLEADA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 249 |  |  | 206 |  |  | 21.2 |  |  |  |  |  |  |
International |  | 293 |  |  | 194 |  |  | 50.9 |  |  |  |  |  |  |
Worldwide |  | 542 |  |  | 400 |  |  | 35.6 |  |  |  |  |  |  |
IMBRUVICA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 270 |  |  | 370 |  |  | (27.1) |  |  |  |  |  |  |
International |  | 557 |  |  | 668 |  |  | (16.6) |  |  |  |  |  |  |
Worldwide |  | 827 |  |  | 1,038 |  |  | (20.3) |  |  |  |  |  |  |
ZYTIGA / abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 16 |  |  | 19 |  |  | (14.0) |  |  |  |  |  |  |
International |  | 229 |  |  | 520 |  |  | (56.0) |  |  |  |  |  |  |
Worldwide |  | 245 |  |  | 539 |  |  | (54.5) |  |  |  |  |  |  |
OTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 92 |  |  | 34 |  |  | * |  |  |  |  |  |
International |  | 70 |  |  | 84 |  |  | (17.2) |  |  |  |  |  |  |
Worldwide |  | 162 |  |  | 118 |  |  | 37.4 |  |  |  |  |  |  |
Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 600 |  |  | 572 |  |  | 4.9 |  |  |  |  |  |  |
International |  | 272 |  |  | 279 |  |  | (2.7) |  |  |  |  |  |  |
Worldwide |  | 872 |  |  | 852 |  |  | 2.4 |  |  |  |  |  |  |
OPSUMIT |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 273 |  |  | 273 |  |  | (0.1) |  |  |  |  |  |  |
International |  | 167 |  |  | 170 |  |  | (1.6) |  |  |  |  |  |  |
Worldwide |  | 440 |  |  | 443 |  |  | (0.7) |  |  |  |  |  |  |
UPTRAVI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 304 |  |  | 269 |  |  | 13.1 |  |  |  |  |  |  |
International |  | 58 |  |  | 56 |  |  | 3.3 |  |  |  |  |  |  |
Worldwide |  | 362 |  |  | 325 |  |  | 11.4 |  |  |  |  |  |  |
OTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 23 |  |  | 30 |  |  | (22.4) |  |  |  |  |  |  |
International |  | 47 |  |  | 53 |  |  | (12.6) |  |  |  |  |  |  |
Worldwide |  | 70 |  |  | 83 |  |  | (16.1) |  |  |  |  |  |  |
Cardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 715 |  |  | 672 |  |  | 6.3 |  |  |  |  |  |  |
International |  | 212 |  |  | 238 |  |  | (10.8) |  |  |  |  |  |  |
Worldwide |  | 927 |  |  | 910 |  |  | 1.8 |  |  |  |  |  |  |
XARELTO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 578 |  |  | 508 |  |  | 13.7 |  |  |  |  |  |  |
International |  | — |  |  | — |  |  | — |  |  |  |  |  |  |
Worldwide |  | 578 |  |  | 508 |  |  | 13.7 |  |  |  |  |  |  |
OTHER(2) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 137 |  |  | 164 |  |  | (16.7) |  |  |  |  |  |  |
International |  | 212 |  |  | 238 |  |  | (10.8) |  |  |  |  |  |  |
Worldwide |  | 349 |  |  | 402 |  |  | (13.2) |  |  |  |  |  |  |
TOTAL PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 7,023 |  |  | 6,632 |  |  | 5.9 |  |  |  |  |  |  |
International |  | 6,390 |  |  | 6,237 |  |  | 2.4 |  |  |  |  |  |  |
Worldwide |  | 13,413 |  |  | 12,869 |  |  | 4.2 |  |  |  |  |  |  |
MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
Interventional Solutions |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 863 |  |  | 494 |  |  | 74.5 |  |  |  |  |  |  |
International |  | 640 |  |  | 597 |  |  | 7.1 |  |  |  |  |  |  |
Worldwide |  | 1,503 |  |  | 1,092 |  |  | 37.6 |  |  |  |  |  |  |
ELECTROPHYSIOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 571 |  |  | 470 |  |  | 21.4 |  |  |  |  |  |  |
International |  | 522 |  |  | 532 |  |  | (1.8) |  |  |  |  |  |  |
Worldwide |  | 1,092 |  |  | 1,002 |  |  | 9.1 |  |  |  |  |  |  |
ABIOMED(3) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 264 |  |  | — |  |  | * |  |  |  |  |  |
International |  | 60 |  |  | — |  |  | * |  |  |  |  |  |
Worldwide |  | 324 |  |  | — |  |  | * |  |  |  |  |  |
OTHER INTERVENTIONAL SOLUTIONS |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 28 |  |  | 24 |  |  | 17.4 |  |  |  |  |  |  |
International |  | 58 |  |  | 65 |  |  | (11.7) |  |  |  |  |  |  |
Worldwide |  | 87 |  |  | 90 |  |  | (3.9) |  |  |  |  |  |  |
Orthopaedics |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,363 |  |  | 1,289 |  |  | 5.8 |  |  |  |  |  |  |
International |  | 881 |  |  | 899 |  |  | (2.0) |  |  |  |  |  |  |
Worldwide |  | 2,245 |  |  | 2,188 |  |  | 2.6 |  |  |  |  |  |  |
HIPS |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 241 |  |  | 225 |  |  | 7.3 |  |  |  |  |  |  |
International |  | 149 |  |  | 164 |  |  | (9.0) |  |  |  |  |  |  |
Worldwide |  | 390 |  |  | 389 |  |  | 0.4 |  |  |  |  |  |  |
KNEES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 226 |  |  | 201 |  |  | 12.4 |  |  |  |  |  |  |
International |  | 142 |  |  | 138 |  |  | 3.4 |  |  |  |  |  |  |
Worldwide |  | 368 |  |  | 339 |  |  | 8.7 |  |  |  |  |  |  |
TRAUMA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 491 |  |  | 475 |  |  | 3.2 |  |  |  |  |  |  |
International |  | 267 |  |  | 273 |  |  | (2.4) |  |  |  |  |  |  |
Worldwide |  | 757 |  |  | 748 |  |  | 1.2 |  |  |  |  |  |  |
SPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 406 |  |  | 387 |  |  | 4.7 |  |  |  |  |  |  |
International |  | 323 |  |  | 324 |  |  | (0.3) |  |  |  |  |  |  |
Worldwide |  | 729 |  |  | 712 |  |  | 2.4 |  |  |  |  |  |  |
Surgery |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 975 |  |  | 921 |  |  | 5.9 |  |  |  |  |  |  |
International |  | 1,459 |  |  | 1,513 |  |  | (3.6) |  |  |  |  |  |  |
Worldwide |  | 2,434 |  |  | 2,434 |  |  | 0.0 |  |  |  |  |  |  |
ADVANCED |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 444 |  |  | 417 |  |  | 6.5 |  |  |  |  |  |  |
International |  | 673 |  |  | 729 |  |  | (7.6) |  |  |  |  |  |  |
Worldwide |  | 1,118 |  |  | 1,146 |  |  | (2.5) |  |  |  |  |  |  |
GENERAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 531 |  |  | 504 |  |  | 5.4 |  |  |  |  |  |  |
International |  | 785 |  |  | 784 |  |  | 0.2 |  |  |  |  |  |  |
Worldwide |  | 1,316 |  |  | 1,288 |  |  | 2.2 |  |  |  |  |  |  |
Vision |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 558 |  |  | 521 |  |  | 7.1 |  |  |  |  |  |  |
International |  | 743 |  |  | 736 |  |  | 0.8 |  |  |  |  |  |  |
Worldwide |  | 1,300 |  |  | 1,257 |  |  | 3.4 |  |  |  |  |  |  |
CONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 444 |  |  | 400 |  |  | 11.1 |  |  |  |  |  |  |
International |  | 509 |  |  | 511 |  |  | (0.3) |  |  |  |  |  |  |
Worldwide |  | 953 |  |  | 910 |  |  | 4.7 |  |  |  |  |  |  |
SURGICAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 114 |  |  | 121 |  |  | (6.0) |  |  |  |  |  |  |
International |  | 233 |  |  | 226 |  |  | 3.3 |  |  |  |  |  |  |
Worldwide |  | 347 |  |  | 347 |  |  | 0.1 |  |  |  |  |  |  |
TOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 3,759 |  |  | 3,225 |  |  | 16.6 |  |  |  |  |  |  |
International |  | 3,722 |  |  | 3,746 |  |  | (0.6) |  |  |  |  |  |  |
Worldwide |  | 7,481 |  |  | 6,971 |  |  | 7.3 |  |  |  |  |  |  |
WORLDWIDE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 12,517 |  |  | 11,414 |  |  | 9.7 |  |  |  |  |  |  |
International |  | 12,229 |  |  | 12,012 |  |  | 1.8 |  |  |  |  |  |  |
Worldwide |  | $ | 24,746 |  |  | 23,426 |  |  | 5.6 | % |  |  |  |  |  |
*Percentage greater than 100% or not meaningful (1) Inclusive of RISPERDAL CONSTA which was previously disclosed separately (2) Inclusive of INVOKANA which was previously disclosed separately (3) Acquired on December 22, 2022 EARNINGS/(LOSS) BEFORE PROVISION FOR TAXES BY SEGMENT
|  | Fiscal First Quarter Ended |  |  |
(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  | Percent Change |  |  |  |  |  |  |  |  |  |  |
Consumer Health(1) |  | $ | 776 |  |  | 686 |  |  | 13.1 | % |  |  |  |  |  |  |  |  |  |  |
Pharmaceutical(2) |  | 4,444 |  |  | 3,924 |  |  | 13.3 |  |  |  |  |  |  |  |  |  |  |  |
MedTech(3) |  | 1,445 |  |  | 1,477 |  |  | (2.2) |  |  |  |  |  |  |  |  |  |  |
Segment earnings before provision for taxes |  | 6,665 |  |  | 6,087 |  |  | 9.5 |  |  |  |  |  |  |  |  |  |  |  |
Less: Expense not allocated to segments (4) |  | 7,102 |  |  | 123 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Less: Consumer Health separation costs |  | 300 |  |  | 102 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Worldwide income/(loss) before tax |  | $ | (737) |  |  | 5,862 |  |  | * |  |  |  |  |  |  |  |  |  |  |
*Percentage greater than 100% or not meaningful (1) Consumer Health includes: •Intangible amortization expense of $0.1 billion in both the fiscal first quarter of 2023 and 2022. (2) Pharmaceutical includes: •Intangible amortization expense of $0.7 billion and $0.8 billion in the fiscal first quarter of 2023 and 2022, respectively. •COVID-19 Vaccine related exit costs of $0.4 billion in the fiscal first quarter of 2023. •A restructuring related charge of $0.1 billion in the fiscal first quarter of 2023. •In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). •Unfavorable changes in the fair value of securities in the fiscal first quarter of 2022 of $0.4 billion. (3) MedTech includes: •Intangible amortization expense of $0.4 billion and $0.3 billion in the fiscal first quarter of 2023 and 2022, respectively. •A restructuring related charge of $0.1 billion in the fiscal first quarter of 2022. (4)Amounts not allocated to segments include interest income/expense and general corporate income/expense. The fiscal first quarter of 2023 includes the incremental $6.9 billion charge related to the talc settlement proposal. See Note 11, Legal Proceedings, for additional details. SALES BY GEOGRAPHIC AREA
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  | Percent Change |  |  |  |  |  |
United States |  | $ | 12,517 |  |  | 11,414 |  |  | 9.7 | % |  |  |  |  |  |
Europe |  | 6,332 |  |  | 6,024 |  |  | 5.1 |  |  |  |  |  |  |
Western Hemisphere, excluding U.S. |  | 1,587 |  |  | 1,482 |  |  | 7.1 |  |  |  |  |  |  |
Asia-Pacific, Africa |  | 4,310 |  |  | 4,506 |  |  | (4.3) |  |  |  |  |  |  |
Total |  | $ | 24,746 |  |  | 23,426 |  |  | 5.6 | % |  |  |  |  |  |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration